Synopsis: After a difficult FY26 marked by margin pressure, stockouts and supply chain disruptions, Vasa Denticity is entering FY27 with a renewed focus on execution. Backed by ace investors Ashish Kacholia and Mukul Mahavir Agrawal, management believes these challenges were operational rather than structural, setting the stage for a return to profitable growth.
The Indian dental industry continues to be one of the most fragmented and underpenetrated healthcare industries in the country. While other categories such as hospitals, diagnostics, and pharmacies have seen rapid technology-led improvements in their distribution channels, the dental distribution landscape remains heavily influenced by dealerships and personal connections.
In such an environment, Vasa Denticity attempts to leverage the Dentalkart platform to digitalise the dental supply chain and build a marketplace for dentists all over India.
Vasa Denticity started FY27 after a tough year.
While revenue growth was steady, profitability was impacted by execution issues acknowledged by management to be a result of its own actions. However, notwithstanding the difficult year, management remains positive about the impact on the company being purely operational and not structural.
The stock continues to attract attention among investors, with ace investor Ashish Kacholia holding a 2.68% stake and investor Mukul Mahavir Agrawal owning 2.36% as of March 2026, according to the latest shareholding pattern. Despite a challenging FY26 marked by margin pressures and execution setbacks, the presence of seasoned investors has kept the spotlight firmly on whether the company can return to profitable growth in FY27.
With a market cap of Rs 650 crore, the shares of Vasa Denticity Ltd are trading at Rs 380 and are trading at a PE of 61 compared to their industry’s PE of 35. The shares have given a return of more than 80% since their listing in June 2023.
Strong growth despite exiting low-margin businesses
Management called FY26 a period marked by both successes and challenges. Firstly, the firm strategically exited Rs 39 crore worth of trading activities in unprofitable segments in order to become more focused on its core business – DentalKart.
The revenue from operations for the company stood at Rs 279 crore in FY26 compared to the FY25 revenue of Rs 241 crore, up by about 16 per cent YoY. However, the net profit stood at Rs 10 crore in FY26, down compared to the Rs 17 crore profit in FY25.
There was impressive growth in the core business, amounting to 33%. In terms of customer acquisition, the firm brought on board 70,000 new dentists for a total of 1.44 lakh. As per management, these customers were mainly drawn from tier-2 and tier-3 areas where the availability of organised supplies was not readily available.
Management believes that the Indian dental market is still in an early stage of penetration into the digital space, providing the firm with considerable potential for expansion. In this case, two-thirds of new customers return within six months.
The profitability setback that changed the narrative
Despite all the good things, FY26 turned out to be rather disappointing from the standpoint of profitability. According to management, the company has indeed underperformed “where it counted”.
Stock-outs of their private label items were identified as the key problem. Considering that private label items generate greater margins than other products, the lack of such products has had an adverse effect on the company’s margins.
While gross margins stood at 34% earlier, in Q4 FY26, the figure went down to 23.7%. At the same time, devaluation of the rupee led to additional costs associated with import products.
The margin pressure has negatively affected the EBITDA performance of the company, much to the dismay of those analysts and investors who have become used to seeing positive trends in prior periods. Management, however, made it very clear that there was no cause for alarm regarding the fundamentals of the business.
Supply chain mistakes and the lessons learned
Perhaps the most notable feature of the earnings call was the management’s ability to take full ownership. The firm admitted that the mistake that happened in its supply chain function led to serious shortages in the stocks of its private-label products. Since these products needed specialised packaging and regulatory approval, the process of stocking took a longer time than anticipated.
At one point, shortage in private-label products was at 33%. Even though it has now been lowered to 14.6%, management conceded that this is above the acceptable range of 5-7%. The company seems to have learned many lessons from this experience.
Management freely admitted that they went too far with their quest for inventory optimisation, leading to consequences such as reduced sales and reduced wallet share of the firm. Instead of concentrating on reducing the inventory, management now plans on balancing growth, efficiency, and availability.
FY27: A return to the core business
One of the most significant messages conveyed through the earnings call was the company’s renewed focus on execution. The company noted that it might have tried to do everything at once in previous years. As such, FY27 is going to be seen as the year when Dentalkart is going to concentrate on building strong foundations for its core business. Management has outlined three urgent priorities: providing better customer service, offering quicker deliveries, and increasing the range of products on offer.
In this regard, customer service should become more effective while quicker deliveries should become possible in regions where customers value speed and pay more. Moreover, the company aims to include additional product categories that dentists buy from specialists outside the platform. The company seems to be focused on excelling rather than trying out all the time.
Faster delivery could become a competitive advantage
The other important aspect which came out frequently was the changing expectations of the customer base. Managers were aware that the quick commerce revolution in India has altered customer behaviour. There is now an expectation for faster delivery for products, especially consumables that dentists will need during their procedure.
Presently, about 60% of orders in tier-one cities get delivered the next day. In the long run, it aims to create small fulfilment nodes or dark stores in many cities so that deliveries can be made in even less time.
However, managers pointed out that there could be a need for 25 small warehouses in order to make deliveries within two days in tier two cities. But it was mentioned that any expansion will come later when all the current operations get stabilised first.
Building an ecosystem beyond transactions
While near-term priorities will continue to focus on execution, the longer-term aspirations for management have wider ambitions. The firm still aims to achieve its long-held dream of becoming an ecosystem for dentists, rather than being just a marketplace platform. Its aspirations extend into areas like digital dentistry, lab offerings, and workflow optimisation as well.
Through its subsidiary, Smileworks, which creates customised prosthesis solutions such as crowns and bridges, it runs at a run rate of around Rs 4.8 crore per year. This, according to the management, should reach Rs 10-12 crore in FY27.
Additionally, it experiments with digital dentistry workflows, which include diagnostics, scanning, treatment planning, 3D printing, and manufacturing processes. While small contributors at present, the lessons derived from these can help build stronger customer relationships over time. It was reiterated that all such efforts would be a supplement to the core platform offering. All attention would thus remain on getting the basics right in FY27.
Growth aspirations remain intact
A significant modification in the way management communicates has been their choice not to be overly aggressive on their short-term outlook. While past goals set by the company of reaching Rs 500-600 crore in revenue were admitted to be a product of the company’s inexperience with managing its affairs in the public markets, management now seems to prefer a loftier goal statement.
It has been stated that the objective is to double the top line every three to four years, and while revenue guidance has not been provided for FY27, a growth of about 30% remains within reach, according to management.
Regarding margins, the company’s management is confident that FY26 was an anomaly and not reflective of the “new normal” going forward, with aspirations of improving EBITDA and aiming for mid-teens margins in three to four years from now. The company also anticipates operational leverage to kick in, as their manpower and warehousing costs will not go up by as much as their revenue.
Can cash flows improve alongside growth?
Another issue where investors were concerned was the cash flow generation. As per the results reported by Vasa Denticity, negative operating cash flows have been experienced by the firm for a few consecutive periods, mainly because of the investment made in inventory to facilitate its growth plans.
The management addressed the issue and re-emphasised that their target was positive free cash flow per share. In their view, there is going to be improvement in cash flow performance because they will make efficient management of their inventory.
They are anticipating that their inventory will continue to be high in the short run; however, they believe that it can be controlled below 120 days and further below 100 days in the long run. It should also be noted that according to their management, at this point in time there are no plans to raise new capital, as the existing capital is enough to manage growth initiatives.
The road to profitable growth
The FY26 earnings call will perhaps be remembered for the shift in tone rather than anything else. While previous issues were blamed solely on external forces, this time management admitted the company’s mistakes and gave details on what had been done to fix the situation. The company still operates in a vast and underdeveloped market with a solid customer base.
The difficulties seen during FY26 including stockouts, inefficiencies in the supply chain, and margins being impacted by competing products, can be fixed through better execution. However, management decided to refocus on the core operations, improve customer experience and provide realistic growth estimates, which is quite a mature strategy of development.
Thus, for investors, an opportunity will be not necessarily about growth but about turning growth into profitable results. If management manages to fix issues like availability of the products and delivery quality and revive the private label programme, FY27 could become a turning point towards profitability for this investor’s ace favourite.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
